The merger with Eos SENOLYTIX is the only near-term catalyst, but it is highly dilutive to current shareholders. Monitor for shareholder vote and merger close; the stock is likely to trade on merger arbitrage dynamics rather than fundamentals. The going concern warning and minimal cash runway add downside risk if the merger fails.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $1.51entry
- T+1 · 3mo ago +1.99%α +2.18% · $1.54
- T+5 · 3mo ago −0.66%α +1.30% · $1.50
- T+20 · 2mo ago −6.62%α −4.88% · $1.41
- T+60 · 11d ago −8.61%α −3.13% · $1.38
Price Chart
How similar events traded
Executive Summary
Pulmatrix reported Q2 2026 financial results with minimal revenue, a net loss of $1.0M, and a cash burn that reduced its cash position to $2.2M. The primary focus is the pending reverse merger with Eos SENOLYTIX, expected to close in Q3 2026, which will leave current Pulmatrix shareholders with only ~6% of the combined entity. The press release also notes a Form S-4 filing for the merger and a strategy to out-license its clinical assets, but the company's going concern warning and the dilutive nature of the merger dominate the outlook.
Key Financial Metrics
Key Facts
- Cash and cash equivalents fell to $2.2M as of June 30, 2026, from $4.1M at year-end 2025.
- Net loss attributable to common stockholders was $1.05M for Q2 2026, compared to $1.55M in Q2 2025.
- The company has a going concern warning, stating cash is sufficient only through the anticipated merger close.
- The proposed merger with Eos SENOLYTIX is expected to close in Q3 2026, with current Pulmatrix shareholders owning ~6% of the combined company.
- A Form S-4 has been filed for the merger, and a $1.0M private placement of Series B Convertible Preferred Stock was completed in March 2026.
- All clinical development is on hold as the company seeks to out-license or monetize its assets.
Financial Impact
Cash burn of ~$1.9M in H1 2026; net loss of $2.2M for the six months ended June 30, 2026.
Risk Factors
- Merger fails to close, leaving Pulmatrix with insufficient cash to continue operations.
- Extreme dilution for current shareholders if merger completes (current holders to own ~6% of combined entity).
- Inability to out-license clinical assets, leaving no value from the existing pipeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302850250 |
Track record
21 reports on PULM
5 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +15.29% at T+60 after the Aug 7, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 9, 20267d ago 425 Neutral 3/10 Entry $1.36 to $1.33 Now $1.33 −1.85% ▼ −1.84% −0.15% vs SPY
- Oct 30, 202617d ago 425 Neutral 3/10 Entry $1.40 to $1.38 Now $1.33 −5.00% ▼ −1.43% +1.27% vs SPY
- Oct 23, 202625d ago EFFECT Bearish 5/10 Entry $1.48 to $1.40 Now $1.33 +10.14% ▲ +5.41% +4.85% vs SPY
- Oct 22, 202625d ago 425 Neutral 4/10 Entry $1.42 to $1.41 Now $1.33 −6.34% ▼ −0.70% −1.41% vs SPY
- Oct 13, 20264w ago 425 Neutral 4/10 Entry $1.38 to $1.43 Now $1.33 −3.62% ▲ +3.62% +4.77% vs SPY
- Oct 7, 20265w ago DEFA14A Neutral 2/10 Entry $1.53 to $1.41 Now $1.33 −12.91% ▼ −7.67% −7.39% vs SPY
- Oct 2, 20266w ago S-3/A Bearish 5/10 Entry $1.48 to $1.43 Now $1.33 +10.14% ▲ +3.38% +3.80% vs SPY
- Sep 28, 20267w ago EFFECT Bearish 5/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 25, 20267w ago DEFM14A Bearish 6/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 23, 20267w ago S-4/A Neutral 2/10 Entry $1.67 to $1.54 Now $1.33 −20.36% ▼ −7.78% −7.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers